International multicenter examination of MOG antibody assays
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received November 14, 2019
- Accepted in final form December 18, 2019
- First Published February 5, 2020.
Author Disclosures
- Markus Reindl, PhD*,
- Kathrin Schanda, MSc,
- Mark Woodhall, PhD,
- Fiona Tea, BSc (Hons),
- Sudarshini Ramanathan, FRACP, PhD,
- Jessica Sagen, BA,
- James P. Fryer, MS,
- John Mills, PhD,
- Bianca Teegen, PhD,
- Swantje Mindorf, MSc,
- Nora Ritter, MSc,
- Ulrike Krummrei, PhD,
- Winfried Stöcker, MD,
- Juliane Eggert, MTA,
- Eoin P. Flanagan, MD,
- Melanie Ramberger, PhD,
- Harald Hegen, MD, PhD,
- Kevin Rostasy, MD,
- Thomas Berger, MD,
- Maria Isabel Leite, MD, DPhil,
- Jacqueline Palace, FRCP, DM,
- Sarosh R. Irani, MD, D.Phil,
- Russell C. Dale, MRCP, PhD,
- Christian Probst, PhD,
- Monika Probst, PhD,
- Fabienne Brilot, PhD,
- Sean J. Pittock, MD and
- Patrick Waters, PhD*
- Markus Reindl, PhD*,
NONE
NONE
NONE
PLOS ONE, academic editor, 2012,
NONE
NONE
NONE
NONE
NONE
The University Hospital and Medical University of Innsbruck (Austria, Markus Reindl) receive payments for antibody assays (NMDAR, AQP4 and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Luebeck, Germany).
NONE
Euroimmun AG, Germany
(1) Austrian Federal Ministry of Science, Research and Education, grant BIG WIG MS, PI, 2013-2017 (2) Austrian Research promotion Agency (FFG), Bridge 1 project Nr. 853209, PI, 2016-2018 (3) Austrian Science Funds (FWF), project W1206, PI, 2007-2018 (4), Austrian Science Funds (FWF), project ZFP326990, PI, 2019-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrin Schanda, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mark Woodhall, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fiona Tea, BSc (Hons),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sudarshini Ramanathan, FRACP, PhD,
Dr Ramanathan has served as a non-remunerated consultant on an advisory board for UCB.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr Ramanathan has received research funding from the Brain Foundation (Australia).
NONE
NONE
NONE
NONE
NONE
NONE
- Jessica Sagen, BA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- James P. Fryer, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John Mills, PhD,
NONE
NONE
NONE
NONE
Mass spectrometric measurement of monoclonal immunoglobulins for diagnosis monoclonal gammopathies
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Mass spectrometric measurement of monoclonal immunoglobulins, Technology licensing to The Binding Site company, 2017.
NONE
NONE
NONE
NONE
- Bianca Teegen, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Clinical immunological laboratory Prof. Dr. Stöcker,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Swantje Mindorf, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
Employed by EUROIMMUN
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
EUROIMMUN
NONE
NONE
NONE
NONE
NONE
- Nora Ritter, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
(1)Euroimmun, employee, 4
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Euroimmun
NONE
NONE
NONE
NONE
NONE
- Ulrike Krummrei, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
employee at EUROIMMUN Medizinsiche Labordiagnostika
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
EUROIMMUN
NONE
NONE
NONE
NONE
NONE
- Winfried Stöcker, MD,
NONE
NONE
NONE
NONE
(1) Stocker W. Verfahren und Vorrichtungen fur Untersuchungen an unbeweglich gemachtem biologischem Material. Europaische Patentanmeldung 0 117 262 (1983).(2) Stocker W., Wandinger K., Komorowski L., Probst C. Verfahren zum Nachweis von Anti-NMDA-Rezeptor-Autoantikorpern zum Einsatz in Diagnoseverfahren. Deutsche Patentanmeldung 10 2010 053 432.3 (2010),(3) Stocker W. Diagnosekit sowie ein Verfahren zur Untersuchung einer menschlichen Patientenprobe auf das Vorhandensein von Neuromyelitis-optica-spezifischen Antikorpern. Deutsche Patentanmeldung 10 2011 011 280.4 (2011).
NONE
WS is a member of the Board of the Euroimmun AG. WS is a shareholder of the Euroimmun AG.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
EUROIMMUN Medizinische Labordiagnostika AG
NONE
NONE
NONE
EUROIMMUN Medizinische Labordiagnostika AG
NONE
- Juliane Eggert, MTA,
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun
NONE
NONE
NONE
NONE
NONE
- Eoin P. Flanagan, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am currently a site primary investigator in a randomized clinical trial on Medi551 in neuromyelitis optica spectrum disorder run by Medimmune. I receive compensation for time related to that activity.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Melanie Ramberger, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Harald Hegen, MD, PhD,
(1) Biogen, commercial
NONE
(1) Bayer Schering, speaker honoraria, funding for travel (2) Biogen, speaker honoraria, funding for travel (3) Merck Serono, speaker honoraria, funding for travel (4) Novartis, speaker honoraria, funding for travel (5) Siemens, speaker honoraria, funding for travel (6) Teva, speaker honoraria, funding for travel (7) Sanofi-Genzyme, speaker honoraria, funding for travel
NONE
NONE
NONE
NONE
(1) Teva Pharmaceuticals Europe
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kevin Rostasy, MD,
Scientific adviser on Fingolimod project-Novartis
NONE
Advisory Board Meeting Novartis and Merck 2017, 2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Berger, MD,
(1) Biogen (2) Celgene (3) MedDay (4) Merck (5) Novartis (6) Roche (7) Sanofi Aventis/Genzyme
NONE
(1) Biogen (2) Celgene (3) Merck (4) Novartis (5) Roche (6) Sanofi Aventis/Genzyme (7) Almirall (8) Bionorica (9) Biologix (10) UCB
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Isabel Leite, MD, DPhil,
NONE
NONE
Dr. Maria Isabel Leite is supported by NHS National Specialised Commissioning Group for Neuromyelitis Optica, UK, and by NIHR Oxford Biomedical Research Centre, and has received travel grant and speaking honoraria from Biogen Idec and travel grant from Novartis.
Neuromuscular Disorders, editorial board member, from January 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jacqueline Palace, FRCP, DM,
All commercial (advisory boards last 2 years) 1) Merck Serono 2) Roche 3) ARGENX 4) Chugai 5) Novartis 6) UCB 7) Alexion
NONE
All commercial (speakers/meetings honorarium last two years) 1) Merck Serono 2) Novartis 3) Viela Bio 4) UCB 5) Roche All commercial (conference support last two years) 5) Chugai 6) MedImmune 7) Alexion
NONE
ISIS Innovation Ltd. To protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis. Reference EP2812690B1
NONE
NONE
All commercial (advisory boards last two years) 1) Merck Serono 2) Roche 3) Argenx 4) Chugai 5) Novartis 6) UCB 7) Alexion Commercial (consultancy) 1) Merck Serono 2) UCB
Please see 3 (speaker/meetings)
NONE
NONE
All commercial (support for research) 1) Merck Serono
NONE
NONE
Grant for research: 1) Multiple Sclerosis Society 2) Guthry Jackson 3) NIHR 4) Medical Research Council 5) MyWare Clinical Training Fellowship
NONE
NONE
NONE
NONE
NONE
NONE
- Sarosh R. Irani, MD, D.Phil,
Encephalitis Society (non-profit, charity). ADC therapeutics and UCB (commercial)
NONE
SRI has received honoraria for speaking at scientific conferences, including the Movement Disorder Society, Dublin Neuroimunology Symposium, Korean Encephalitis meeting and Bethel Epilepsy Symposium.
NONE
SRI receives royalties on patent application WO/2010/046716 entitled 'Neurological Autoimmune Disorders'. The patent has been licensed to Euroimmun AG for the development of assays for LGI1 and other VGKC-complex antibodies.
NONE
NONE
1. Commercial. MedImmune Ltd. 2. ADCT 3. Minnetronix Neuro Inc 4. UCB Pharma 5. Medicolegal projects (various)
NONE
NONE
NONE
Commercial: SRI has received research funding from UCB, CSL Behring and ONO pharmaceuticals
S.R.I has received a NIHR fellowship, Department of Health, UK to fund his DPhil/PhD
SRI received funding support from a Wellcome Intermediate Clinical Fellowship, BMA Research Grants - Vera Down grant, the Fulbright UK- US commission and the MS society (2012-2013).
NONE
NONE
NONE
For VGKC-complex antibody patent, as described above. Royalties paid by OUI, University of Oxford's IP company in 2012 and 2013.
NONE
NONE
NONE
- Russell C. Dale, MRCP, PhD,
National Blood Authority. Federal, not for profit
NONE
received an honoraria for lecturing from Biogen Idec and Bristol-Myers-Squibb
Editorial advisory board member of MSARD Editorial board member of Neurology: Neuroimmunology and Neuroinflammation Editorial board member of European Journal of Paediatric Neurology
NONE
Biogen Idec honoraria in 2008 and Bristol-Myers-Squibb in 2015
NONE
NONE
NONE
NONE
NONE
NONE
NHMRC national grant in 2011 national grant for encephalitis study NHMRC practitioner fellowship 2014-8 NHMRC project grant 2015, 2018 NHMRC partnership grant 2018
Multiple Sclerosis Research Australia 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Probst, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun, full-time employee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun
NONE
NONE
NONE
NONE
NONE
- Monika Probst, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
EUROIMMUN
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
EUROIMMUN
NONE
NONE
NONE
NONE
NONE
- Fabienne Brilot, PhD,
NONE
NONE
(1) Biogen Idec, speaking honoraria (2) Merck Serono, speaking honoraria
(1)Journal of Visualized Experiments, associate editor, 2 years, no compensation received (2) Section Multiple sclerosis and Neuroimmunology, Frontiers in Immunology and Frontiers in Neurology, Associate editor, 3. years, no compensation received
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Health and Medical Research Council Australia (2) Multiple Sclerosis Research Australia (MSRA)
NONE
(1) The Star Scientific Foundation Australia (2) The Trish Multiple Sclerosis Foundation Australia (3) Petre Foundation Australia
NONE
NONE
NONE
NONE
NONE
NONE
- Sean J. Pittock, MD and
Alexion Pharmaceutical Advisory Board Medimmune/Viele Bio Advisory Board UCB pharmaceuticals Astellas
NONE
NONE
NONE
Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) - Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, and a patent Patent# 9,891,219B2 (Application#12-573942) - Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued. Dr Pittock has a patent pending for GFAP, Septin-5, Kelch11 and MAP1B autoantibodies as biomarkers of neurological autoimmunity.
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
No activity to report. I am a salaried employee of Mayo Clinic and salary is fixed specialty dependent and not impacted by test volume or laboratory income.
NONE
Dr Pittock has received research funding from Grifols, Medimmune/Viela Bio, Alexion and AEA (Autoimmune Encephalitis Associations).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Waters, PhD*
Served on the advisory board for F. Hoffmann-La Roche Ltd.
NONE
Honoraria UBC and Alexion.
NONE
Assays for the detection of antibodies to LGI1, CASPR2, Tag-1 and GABA-A Receptor (g2 subunit).
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun AG
NONE
NONE
NONE
NONE
NONE
Patents for CASPR2, LGI1, TAG-1 and GABA-A Receptor (g2 subunit).
NONE
NONE
NONE
- From the Clinical Department of Neurology (M. Reindl, K.S., M. Ramberger, H.H.), Medical University of Innsbruck, Innsbruck, Austria; Oxford Autoimmune Neurology Group (M.W., M. Ramberger, M.I.L., J.P., S.R.I., P.W.), Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom; Brain Autoimmunity Group (F.T., S.R., R.C.D., F.B.), Kids Neuroscience Centre at Kids Research at the Children's Hospital at Westmead, Brain and Mind Centre, University of Sydney, New South Wales, Australia; Department of Neurology (J.S., J.P.F., J.M., E.P.F., S.J.P.), Mayo Clinic, Rochester, MN; Euroimmun Medizinische Labordiagnostika AG (B.T., S.M., N.R., U.K., W.S., C.P.), Lübeck, Germany; Institute for Quality Assurance (ifQ) affiliated to Euroimmun (J.E., M.P.), Lübeck, Germany; Paediatric Neurology (K.R.), Witten/Herdecke University, Children's Hospital Datteln, Datteln, Germany; and Department of Neurology (T.B.), Medical University of Vienna, Austria.
- Correspondence
Dr. Reindl markus.reindl{at}i-med.ac.at or Dr. Brilot fabienne.brilot{at}sydney.edu.au or Dr. Pittock pittock.sean{at}mayo.edu or Dr. Waters paddy.waters{at}ndcn.ox.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Fulminant demyelinating encephalomyelitisInsights from antibody studies and neuropathologyFranziska Di Pauli, Romana Höftberger, Markus Reindl et al.Neurology - Neuroimmunology Neuroinflammation, November 04, 2015 -
Article
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersDouglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto et al.Neurology, January 10, 2014 -
Article
MOG cell-based assay detects non-MS patients with inflammatory neurologic diseasePatrick Waters, Mark Woodhall, Kevin C. O'Connor et al.Neurology - Neuroimmunology Neuroinflammation, March 19, 2015 -
Article
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W. Reddel, Andrew Henderson et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2014